Shoreline Biosciences

What Shoreline Biosciences does

Shoreline Biosciences is a clinical-stage biotechnology company developing immunotherapies derived from induced pluripotent stem cells (iPSCs), with the stated goal of producing allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, in contrast to patient-specific autologous CAR-T approaches. The company's core technology is its iPSC platform, which is applied to generate cell-based immunotherapies targeting cancer and other serious diseases. The pipeline and platform are positioned to address limitations of current autologous cell therapies, including long manufacturing turnaround times, patient-specific processing constraints, and scalability bottlenecks.

The business model is partnership- and licensing-driven rather than direct commercialization. Shoreline raises venture capital and enters into strategic co-development agreements with established pharmaceutical companies to advance its candidates through development and toward commercialization. Its two named anchor partners are Kite Pharmaceuticals (a Gilead Sciences company specializing in CAR-T cell therapies) and BeiGene (a global biopharmaceutical company with broad oncology and immunology capabilities), both announced in November 2021. Revenue, when and if it materializes, would come in the form of milestone payments and royalties under these licensing/co-development arrangements; the company has no approved products and no disclosed pricing model. Headcount sits in the 51-100 range, consistent with an early-clinical biotech scaling manufacturing capabilities alongside pipeline growth.

Shoreline is headquartered in La Jolla, California (United States), was founded in 2020, and has raised approximately $186 million across three disclosed funding rounds between July 2020 and November 2021, with the largest $140 million round led by Ally Bridge Group and supported by a 15-investor syndicate including both pharma partners (Kite Pharma, BeiGene). The data available in source materials ends in late 2021 and does not reflect any subsequent clinical milestones, additional financings, or pipeline updates.

Name

Shoreline Biosciences

Legal name

Shoreline Biosciences

Website

https://shorelinebio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Shoreline Biosciences is a La Jolla-based clinical-stage biotechnology company developing allogeneic iPSC-derived cell immunotherapies for cancer and other serious diseases, advancing its pipeline through strategic co-development partnerships with Kite Pharmaceuticals and BeiGene.

Ownership category

akta.pro rank

Product category

Cell Immunotherapy Development

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Stem Cell–Based Regenerative Therapies (HLAAAGAA)

Keywords

• Cell immunotherapy development
• IPSC-based therapies
• Allogeneic cell therapy
• Oncology cell therapy
• Regenerative medicine platform

Headquarters

HQ city

La Jolla

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations

Revenue model

1. iPSC-based Immunotherapy Development and Licensing: As a pre-commercial biotechnology company, Shoreline Biosciences generates value through partnership agreements with pharmaceutical companies for the co-development of cell therapies, potentially receiving milestone payments and royalties upon successful commercialization of partnered therapies.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Shoreline Biosciences develops immunotherapies derived from induced pluripotent stem cells (iPSCs) intended to treat seriously ill patients, particularly cancer. The company focuses on allogeneic (off-the-shelf) cell therapies that can be manufactured at scale, addressing limitations of autologous CAR-T approaches. Pipeline development is conducted through strategic co-development partnerships with pharmaceutical companies.

Product overview

Shoreline Biosciences is a biotechnology company developing iPSC-based cell immunotherapies. The company operates a pipeline-focused approach with its core iPSC-derived immunotherapies platform, supported by strategic partnerships with Kite Pharmaceuticals and BeiGene for developing cell therapies targeting various diseases. The company's product portfolio centers on allogeneic cell therapies manufactured from iPSCs, with the financing supporting pipeline growth and manufacturing capabilities expansion.

Differentiator

Problem solved

Functional benefit

Products and services

• iPSC-based Immunotherapies Cell immunotherapies derived from induced pluripotent stem cells (iPSCs) targeting various diseases including cancer; designed to enable allogeneic, off-the-shelf cell therapy manufacturing at scale. Developed for pharmaceutical partners such as Kite Pharmaceuticals and BeiGene.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Kite PharmaceuticalscoreStrategic or Co-development Partner · 2 November 2021Shoreline Biosciences entered into a strategic partnership with Kite Pharmaceuticals to develop cell therapies targeting various diseases. Kite Pharma is a Gilead Sciences company specializing in CAR-T cell therapies, bringing expertise in cell therapy manufacturing and commercialization to the partnership.
• BeiGenecoreStrategic or Co-development Partner · 2 November 2021Shoreline Biosciences partnered with BeiGene, a global biopharmaceutical company, to develop cell therapies targeting various diseases. The partnership leverages BeiGene's global development and commercialization capabilities in oncology and immunology.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Precision BioSciences: Precision BioSciences develops allogeneic CAR-T cell therapies using ARCUS gene editing. Direct cell therapy peer targeting oncology with off-the-shelf, scalable manufacturing.
• Century Therapeutics: Century Therapeutics develops iPSC-derived allogeneic cell therapies (NK and T cells) with engineered resistance to the tumor microenvironment. Closely overlapping platform technology and indication focus with Shoreline.
• Allogene Therapeutics: Allogene is a pioneer in allogeneic CAR-T cell therapy, using healthy donor cells (rather than iPSC) for off-the-shelf products. Direct allogeneic cell therapy peer and leading competitor in the same commercial category Shoreline targets.
• Adicet Bio: Adicet Bio develops off-the-shelf allogeneic gamma-delta T-cell therapies for cancer and autoimmune disease. Directly comparable to Shoreline in targeting allogeneic, scalable cell therapy manufacturing.
• Fate Therapeutics: Fate Therapeutics is the leading clinical-stage developer of iPSC-derived NK and T-cell immunotherapies — directly comparable to Shoreline's core iPSC allogeneic platform. Both companies pursue off-the-shelf, multiplexed engineered cell therapies for oncology.
• Nkarta Therapeutics: Nkarta develops engineered NK cell therapies for cancer, including allogeneic, off-the-shelf approaches. Comparable as a cell therapy peer targeting hematologic and solid tumors with a partner-validated platform.
• Caribou Biosciences: Caribou develops allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable peer in the allogeneic cell therapy category with a similar partner-driven business model.

Emerging players

• Editas Medicine: Editas Medicine develops CRISPR-based gene-edited cell therapies, including allogeneic NK and T-cell approaches. Comparable as a gene-editing cell therapy peer with overlapping technology platforms.

Broad incumbents

• Cellectis: Cellectis is a clinical-stage gene-editing company developing allogeneic CAR-T (UCART) therapies and TALEN-edited cell products. Comparable as a broader allogeneic cell therapy player with established manufacturing platforms.
• CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing biotech with allogeneic cell therapy programs (including CAR-T) and a Vertex partnership. Comparable as a broad incumbent in gene-edited cell therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds3 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shoreline Biosciences